Key Points
- The Joint Committee on Vaccination and Immunisation (JCVI) has recommended a routine MenB vaccine offer for adolescents around age 15.
- The recommendation would give one dose to those born on or after 1 May 2015, described by JCVI as “primed adolescents.”
- JCVI also strongly supports two-dose catch-up vaccination for older teenagers who missed earlier protection.
- The Department of Health and Social Care (DHSC) will now consider the recommendation before any change to the NHS vaccination schedule is made.
- The review was prompted by an unprecedented MenB outbreak in Kent earlier in 2026.
- The government said recent evidence on vaccine effectiveness, outbreak patterns, and broader public-health protection informed the recommendation.
- JCVI said the infant MenB vaccine introduced in 2015 has been highly effective, but adolescents may need added protection later in life.
London (King County Insider) July 17, 2026 – The Joint Committee on Vaccination and Immunisation has recommended a routine MenB vaccination offer for teenagers around age 15, following a severe outbreak in Kent and a wider review of recent evidence on protection against invasive meningococcal disease.
What did JCVI recommend?
As reported by the UK Health Security Agency, JCVI said adolescents who were eligible for MenB vaccination in infancy should receive a routine single dose at around age 15. The committee also backed a two-dose catch-up offer for young people who were not covered by the planned routine programme or who missed earlier protection. JCVI said the first cohort directly covered by the new routine proposal would reach age 15 in 2030.
Why was the review triggered?
JCVI’s latest review followed what the government described as an unprecedented MenB outbreak in Kent earlier this year. The government said the outbreak prompted the Secretary of State for Health and Social Care to request an urgent review of adolescent vaccination policy. JCVI said it also considered updated evidence on disease trends, outbreak data, vaccine effectiveness, and possible broader benefits of the 4CMenB vaccine.
How does the vaccine schedule change?
The current infant MenB vaccine programme began after JCVI recommended it in 2014, and it was introduced in 2015. JCVI said the infant programme has been highly effective and provides strong protection for at least five years after vaccination. The committee said a new adolescent programme is intended to extend protection into the years when risk may rise again.
What did officials say?
Prof. Wei Shen Lim, chair of JCVI, said the committee wanted to help protect eligible young people before they head to university or college, where the one-off summer 2026 programme is already available for some groups. He also said MenB is a rare but serious illness that can have a devastating impact, and he thanked families and charities who contributed evidence during the review. DHSC said it will now consider the recommendation and decide whether the NHS MenB schedule should change.
What happens next?
The recommendation is not yet a final policy change, because the government must still decide whether to accept it. JCVI said the planned routine programme would add protection for adolescents at a later age than the infant series, while catch-up doses would help cover those missed by earlier offers. The government also noted that a one-off MenB vaccine offer is already available for eligible young people this summer, including those entering university or residential further education settings in autumn 2026.
Background of the development
Meningitis B is a serious bacterial infection that can spread quickly and cause life-threatening illness, which is why public-health authorities closely review vaccination policy after outbreaks. In Kent, the outbreak led to emergency public-health action and renewed scrutiny of whether immunity from infant vaccination should be reinforced in adolescence. JCVI’s earlier infant recommendation remains the basis of the current programme, but the new advice reflects both outbreak experience and newer evidence on vaccine impact in older children and young adults.
Prediction
For teenagers and families, this development could mean an extra layer of protection during secondary school, college transition, and early adulthood if the government accepts the advice. For schools, colleges, and local health services, it could mean another routine vaccine age point to communicate and organize. For public health authorities, the likely effect would be broader MenB coverage and a lower chance of future outbreaks spreading among older adolescents.
